12月20日,福泰制药(Vertex)宣布新一代三联疗法Alyftrek(Vanzacaftor/Tezacaftor/Deutivacaftor,简称Vanza三联疗法)用于治疗囊性纤维化(CF)的新药申请(NDA)获FDA批准。CF是一种罕见的、进行性、缩短寿命的遗传病,累及肺、肝、胰腺、胃肠道、鼻窦、汗腺和生殖道。全球有超过9.2万例CF患者。CF由CFTR基因中的某些突变导致CFTR蛋白...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.